Direct Flow aims to use heart valve giants’ experience against them

Direct Flow Medical CEO Bernie Lyons

Being one of the smallest players on the field means you’ve got to differentiate yourself to stand out against the titans of the game, and that’s what Direct Flow Medical CEO Bernie Lyons aims to do.

Direct Flow and its transcatheter aortic valve implantation technology must face down some of the medical device industry’s largest players, including Medtronic (NYSE:MDT), Boston Scientific (NYSE:BSX), Edwards Lifesciences (NYSE:EW) and St. Jude Medical (NYSE:STJ), in order to gain share in the TAVI arena. Lyons told MassDevice.com that he has simple plan – he’s gaining from others’ experiences.

"The beauty of this market is that the giants have done a great job of developing it," Lyons told us. "In fact, we predicated the company on what we learned from the very early users."

Direct Flow was started in 2004 with the intention of responding to a growing concern among physicians using TAVI technology. Early generations of the heart valves, although effective and comparable to surgical valve replacement, were more prone to a type of valve leakage that could cause death, according to some studies. The devices also came with a steep learning curve for physicians, who usually have only 1 chance at implanting the devices.

Direct Flow developed its bovine tissue valve with an inflatable, flexible cuff to address concerns about leakage, or valve regurgitation, as well as to simplify the implantation process. That design helps the device fit different aortic valve anatomies, Lyons said

"We use a metal-free frame for our valve, which, unlike others, allows us to address some of the key clinical issues in the marketplace," he explained. "Because we have the metal-free structure, it will conform to any annulus in terms of its placement, thereby virtually eliminating aortic regurgitation."

“The beauty of this market is that the giants have done a great job of developing it.”

Other TAVI players have also taken steps to reduce the incidence of regurgitation in their devices. Medtech giant Medtronic in October 2012 reported early results from a pivotal CE Mark trial of its Engager TAVI system, touting reduced valve leakage and easier device deployment. Similar reports came from an early feasibility study of Boston Scientific’s Lotus device, with investigators saying it all but eliminated aortic regurgitation and allowed precise positioning on the 1st attempt.

Direct Flow’s TAVI device is also fully repositionable and retrievable, even after full deployment, Lyons said. Physicians can assess the placement of the device and make adjustments as necessary before completing the procedure.

"The most important thing that the 1st physicians that used the early technology told us was that they wanted something repositionable, so that you could optimize its placement," Lyons said. "You don’t want to treat these patients with aortic stenosis and leave them compromised with another disease of aortic regurgitation."

The flexibility of the metal-free structure also allows the valve to come with the lowest-profile, most flexible delivery system, which further eases the process of threading the device through the body and into the heart, he added.

"This technology really does offer something unique to the marketplace. Because of that ability to optimize and assess the outcome before deploying it’s what we consider a true 2nd-generation device," Lyons told us.

Many elements of Direct Flow’s engineering and market strategy came from watching its predecessors, capitalizing where possible on more than 10 years of TAVI experience. Choosing to avoid a metal structure was 1 of the key factors in differentiating its TAVI system from others, but Direct Flow also took cues from their regulatory bids and clinical programs as well.

“Being in this industry for over 25 years, clinical data is the most important thing to the marketplace.”

"We watched them in all their approaches, and certainly working through the regulatory and clinical process has been very helpful to us, by seeing how they’ve done it," Lyons said. "In our Discover trial, which is a CE Mark trial, we used a core lab, just like the FDA requires and has been done in the U.S. for [Edwards Lifesciences’] Partner I and Partner II trials."

Direct Flow used the Discover trial results to help land a recent CE Mark approval for the European market. The company said it plans to use the data for its FDA application as well. Using an independent core lab to assess all the hemodynamic outcomes for its subjects means the study "is to the standards of the U.S. FDA," Lyons said, adding that Direct Flow was the 1st to publish TAVI study data in that manner.

"Being in this industry for over 25 years, clinical data is the most important thing to the marketplace," he said.

The Discover study demonstrated of Direct Flow’s TAVI system met primary its mortality endpoints, with no incidents of major vascular complications and with 95% of patients experiencing mild or less paravalvular regurgitation at 30 days. The company has begun the FDA submission process, is in "constant discussions" with health regulators and hopes to begin an investigational device exemption study in the 2nd half of this year, Lyons told us.

Edwards Lifesciences is the only medical device maker with FDA permission to market a TAVI system in the U.S., having won approval in November 2011, but others are close. Medtronic’s CoreValve was the 1st valve to hit the global market, landing on European shelves in 2007. But the world’s largest medical device company said it doesn’t expect its TAVI device to win FDA approval until 2014. St. Jude Medical expects to begin U.S. IDE trials this year for its Portico entrant.

For its part, Direct Flow hopes to leverage strong clinical results to draw market share away from well-established industry players.

"Aortic regurgitation is the number 1 clinical issue that our physicians are dealing with for these patients," Lyons said. "Because of our unique design and ability to eliminate that problem, we think that clinicians will accept this technology – despite us being a small, privately held company."

RSS From Medical Design & Outsourcing

  • GlobTek presents its latest level VI AC/DC adapter and connverter
    T-43086-WWVV-X.X-Q Model is an addition to GlobTek’s Level VI compliant GT-43086 family and represents GlobTek’s 6 Watt wall plug-in series of AC/DC adapters (power supplies and chargers) with International Interchangeable blades. GlobTek’s changeable input blade system with individual field replaceable input plugs, including: North America and Japan NEMA 1-15P, Australian, UK BS 1363, European CEE […]
  • Sanmina’s familiarity with FDA gets skin treatment product to market fast
    The medical market for cosmetic devices is booming. However, quickly launching new products to meet demand is becoming more challenging because device manufactures face increased regulatory scrutiny. To help meet regulatory requirements, aesthetic and other medical-device OEMs are partnering with electronics manufacturing services (EMS) companies that also offer expertise with the FDA filings necessary to […]
  • Fluid connectors and quick disconnects for IVD equipment from CPC
    Colder Products Company (CPC) offers thousands of tubing connectors, quick disconnects and fittings for smart fluid handling in IVD and analytical equipment. Non-spill connectors speed testing throughput by eliminating drips, preventing air inclusion and increasing operator safety. Panel mount connectors can be added to existing equipment or bottle caps to provide secure, leak-free connections. Puncture […]
  • 310 Watt desktop medical power supply meets efficiency level VI requirements
    Power Partners releases a new 310 Watt medical grade desktop power supply from their PEAMD Series of AC and DC adapters. The 310 Watt unit is packed for ideal performance inside a compact case measuring 7.8 x 4 x 2 in. with a weight of only 3 lbs. The PEAMD310 Series is approved to the latest […]
  • Saelig introduces Multiple Instrument System MIS4 universal test system
    Saelig Company has introduced the ABI Electronics’ Multiple Instrument Station MIS4, an all-in-one testing tool that provides all commonly required test instruments in one compact programmable hardware module, mounted in a compact case or installed in a PC-drive bay. Controlled by ABI’s sophisticated SYSTEM 8 Ultimate PC software with a simple yet programmable operator interface, […]
  • AssurX announces document management software update for small to mid-size companies in FDA regulated industries
    AssurX, an enterprise quality management, risk and regulatory compliance solution provider, announces the release of the latest update to their AssurX document management software. The document management solution provides a cost-effective solution for small to medium sized companies faced with streamlined operations and is fully compliant for FDA regulated industries. Ideal solution for small to […]
  • Saelig presents new Amplicon Impact-R 1100F series computer
    Saelig Company announces the Amplicon Impact-R 1100F series, a fanless system powered by the Intel ATOM D2550 processor. Configured with a high performance 2.5 in. MLC Solid State Drive (SSD), the Impact-R 1100F series is a silent controller system. With options for multiple serial communication ports, the Impact-R 1100F can offer up seven DB9 connections […]
  • Gerresheimer to acquire Centor
    Gerresheimer AG, a partner to the global pharmacy and healthcare industry, will further extend its pharmaceutical packaging business with the acquisition of Centor. Gerresheimer has reached an agreement with Nemera Development S.A. to acquire 100% of the share capital of Centor US Holding. “Centor is the highly profitable market leader for plastic vials and closures in […]
  • Methods Machine Tools presents the new Nakamura-Tome NTRX-300
    Methods Machine Tools, a developer of precision machine tools and automation, has introduced the new Nakamura-Tome NTRX-300, a multitasking turning center featuring complete parts machining in one operation, with a built-in load and unload automation system and advanced operator recognition management software. The NTRX-300 features true opposing twin spindles: an 8 in. A2-6 25 HP or […]
  • MSC Apex Diamond Python and Smart Midsurface speeds modeling to validation
    MSC Software announced a new release of MSC Apex, the company’s award-winning next generation Computer Aided Engineering (CAE) platform. The MSC Apex Diamond Python release introduces: · The fourth release of MSC Apex Modeler is a CAE Specific direct modeling and meshing solution that streamlines CAD clean-up, simplification and meshing workflow. New in this release is […]
  • Quality Metrics: FDA’s plan for a key set of measurements to help ensure manufacturers are producing quality medications
    Editor’s Note: This article is written by Ashley Boam and Mary Malarkey from the “FDA Voice” blog. Boam is an FDA’s acting Director of the Office of Policy for Pharmaceutical Quality, the Office of Pharmaceutical Quality and the Center for Drug Evaluation and Research. Malarkey is an FDA’s Director if the Office of Compliance and Biologics Quality […]

Leave a Reply